Insights
Bringing cardiovascular screening closer to home in rural communities

After reaching nearly 10,000 patients in its first phase, a community pharmacy program supported by Bristol Myers Squibb is expanding to six additional states to bring cardiovascular screening and support closer to people in rural communities.

Pharmacist speaking with a patient at an independent community pharmacy

She felt perfectly healthy. She exercised regularly, and her checkups had gone well. But during a cardiovascular risk screening at Semmes Pharmacy in Alabama, the results pointed to a possible irregular heart rhythm associated with stroke risk.

The pharmacy team referred her to a cardiologist for further evaluation.

Her experience illustrates why access matters in many rural communities: Identifying a health risk early depends in part on having access to screening and support close to home.

That's what the National Community Pharmacists Association (NCPA) Innovation Center, CPESN® USA and Bristol Myers Squibb are working to address through a program that brings cardiovascular screening and support into independent pharmacies serving rural, medically underserved communities.

Why local pharmacies matter


Heart disease remains the leading cause of death in the United States. In rural communities, the burden is greater, with research showing cardiovascular death rates about 1.5 times higher in rural areas than in urban areas as of 2022.

Access to care is part of that challenge. In many rural communities, the local pharmacy is a familiar and convenient place for people to connect with a health care professional.

The program builds on that existing relationship by equipping pharmacy teams with new skills., Pharmacists receive training to screen and counsel patients on cardiovascular risk, while pharmacy technicians receive training to become certified community health workers, helping connect people with health care and social services when additional support is needed.

What the first phase revealed

As the program got underway, the focus was on testing whether independent pharmacies could help identify cardiovascular risks and address barriers to care in rural communities. Six months later, the first phase offers an early look at what happened when that model was put into practice.

Twenty-five independent pharmacies across Alabama, Arkansas, Kentucky, Louisiana, Mississippi and Missouri reached nearly 10,000 patients through more than 11,000 encounters.

The screenings identified risks that might otherwise have gone unnoticed. Pharmacy teams identified approximately 400 patients with an abnormal heart rhythm and referred 81% of them to a physician. When patients didn't have a primary care physician, pharmacy teams worked to connect them with one.

The program also looked at barriers beyond cardiovascular risk. Screening during pharmacy encounters identified unmet needs involving access to care, transportation, finances and health literacy, factors that can affect whether people are able to get the care and support they need.

"In many rural areas, the pharmacist is the most accessible health care provider," said NCPA CEO B. Douglas Hoey. "Those pharmacists are educated and trained to provide life-saving clinical services like these, but our health care system does not currently take full advantage of the value they offer."

For pharmacists involved in the program, those numbers represent individual conversations with people in their communities.

"For me, it's about more than a screening," said Holly Williamson, a clinical pharmacist at Semmes Pharmacy in Alabama. "It's about making sure patients feel informed, supported, and empowered to take care of their health."

Expanding the model and learning what comes next


Phase 2 builds on what the partners learned in the first six months. The original 25 pharmacies will continue participating, while up to 50 additional pharmacies will join across Florida, Idaho, Nevada, North Carolina, Oregon and Texas.

Over the next six months, the program aims to screen another 15,000 people for cardiovascular risk. It will also follow health outcomes among patients identified as at-risk during Phase 1.

Expanding to communities in additional states will give the partners an opportunity to learn how the model works across different health care environments while continuing to focus on AFib, stroke risk and patient education.

"Phase 1 showed us what is possible when care meets people where they already are," said Al Reba, senior vice president, Immunology & Cardiovascular Commercialization at BMS. "Many of these patients felt fine and had no idea they were at risk, and a conversation with someone they trust changed that. In Phase 2, we want to learn how to make that access last and what it means for patients' health over time."

The findings could help the partners better understand whether the model can be expanded to other communities and contribute evidence about the role community pharmacists can play in improving access to preventive cardiovascular care.

"Population health works when care reaches people before a crisis does," said Andrew Whitehead, vice president, head of Population Health at BMS. "By pairing pharmacist screenings with community health workers who can connect patients to the resources they need, this program identifies health risks and helps remove the barriers that keep people from getting care."

Looking ahead


For the woman who walked into Semmes Pharmacy feeling healthy, a screening at a familiar community pharmacy led to a referral she didn't know she might need.

Phase 2 will test whether that opportunity can reach thousands more people and what happens after a health risk is identified. NCPA plans to share results from the expanded program in mid-2027.

Learn more about how Bristol Myers Squibb is advancing population health.

More stories

    About Bristol Myers Squibb

    Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.